Effects of substance P and vasoactive intestinal polypeptide on contractile activity and epithelial transport in the ferret jejunum.
Previous studies in the ferret demonstrated that vagal nerve stimulation induced an atropine-resistant water secretion. Substance P and vasoactive intestinal polypeptide are possible mediators of this secretory response. The objectives of this study were to investigate the in vivo effects of substance P and vasoactive intestinal polypeptide on the jejunal musculature and epithelium. Substance P caused an increase in jejunal motility, water secretion, and transmural potential difference. Cholinergic blockade did not affect the substance P-induced contractions, but did reduce the increase in transmural potential difference, suggesting an inhibition of water secretion. Vasoactive intestinal polypeptide abolished motor activity; however, it induced an increase in transmural potential difference that was atropine and tetrodotoxin resistant. By immunohistochemical methods, immunoreactive vasoactive intestinal polypeptide and immunoreactive substance P were localized to both nerve cell bodies and nerve fibers in the ferret intestine. Determination of intestinal concentrations of vasoactive intestinal polypeptide and substance P in the ferret showed concentrations of these two neuropeptides that were similar to those in human intestine and demonstrated much higher concentrations of these substances in the muscular layer than in the epithelial layer. Our data demonstrate that in the ferret substance P excites and vasoactive intestinal polypeptide inhibits jejunal motor activity. However, both peptides increase water secretion. Our results suggest that in response to vagal stimulation, neuronally released substance P or vasoactive intestinal polypeptide may participate in the atropine-resistant water secretion.
Greenwood
B
B
Department of Pharmacology, Medical College of Wisconsin, Milwaukee.
Doolittle
T
T
See
N A
NA
Koch
T R
TR
Dodds
W J
WJ
Davison
J S
JS
D000200:Action Potentials; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001692:Biological Transport; D004848:Epithelium / Q000032:analysis; D005289:Ferrets; D005769:Gastrointestinal Motility / Q000187:drug effects; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000032:analysis; D007583:Jejunum / Q000032:analysis / Q000187:drug effects* / Q000294:innervation / Q000502:physiology; D008297:Male; D009132:Muscles / Q000032:analysis / Q000187:drug effects / Q000294:innervation; D009197:Myenteric Plexus / Q000032:analysis; D013373:Substance P / Q000032:analysis / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000032:analysis / Q000494:pharmacology*
D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D013779:Tetrodotoxin; D001285:Atropine